USE OF TYROSINE KINASE INHIBITOR TO TREAT DIABETES

摘要

The invention relates to the use of a c-Abl-. PDGF-R-, or c-kit- tyrosine kinase inhibitor, e.g. 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, Bis (1H-2-indolyl)-1-methanones, AG1295, CT52923, RP-1776; GFB-111; pyrrolo[3,4-c]-beta-carboline-diones, SU 102, AG1296, RPR101511A, CDP 860, Zvegf3, CP673451, PD 170262, KI 6783, KN 1022, AG 13736, CHIR 258, MLN 518, SU 11248, Leflunomide, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of diabetes, e.g. type I diabetes, type II diabetes.